AEON Biopharma, Inc. (AEON)
NYSE: AEON · Pharmaceutical Preparations · Irvine, CA · filing with the SEC since 2020
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Report filed | Mar 30, 2026 | Mar 24, 2025 | Mar 29, 2024 | Feb 22, 2023 | Mar 28, 2022 | Mar 31, 2021 |
| Research and development | 4,094,000 | 14,181,000 | · | 34,754,000 | · | · |
| Selling, general and administrative | 12,208,000 | 13,643,000 | · | 13,675,000 | · | · |
| Total operating expenses | 12,803,000 | -72,985,000 | · | 48,429,000 | · | · |
| Total costs and expenses | · | · | · | 3,325,605 | 1,935,943 | · |
| Operating income | -12,803,000 | 72,985,000 | · | -48,429,000r | -1,935,943 | · |
| Interest and investment income | · | · | · | 3,706,667 | 79,687 | · |
| Other income (expense), net | 290,000 | 95,000 | · | 289,000 | · | · |
| Total non-operating income (expense) | -26,419,000 | -30,980,000 | · | -4,127,000r | 10,136,774 | · |
| Income before income taxes | -39,222,000 | 42,005,000 | · | -52,556,000r | 8,200,831 | · |
| Income tax expense | 0 | 0 | · | 0r | · | · |
| Net income including non-controlling interests | -39,222,000 | 42,005,000 | · | -52,556,000r | 8,200,831 | · |
| Net income | -39,222,000 | 42,005,000 | · | -52,556,000r | 8,200,831 | · |
| Net income to common shareholders | -39,222,000 | 42,005,000 | · | -52,556,000 | · | · |
| Earnings per share, basic | -3.95 | 77.74 | · | -0.38 | · | · |
| Earnings per share, diluted | -3.95 | 72.93 | · | -0.38 | · | · |
| Weighted average shares, basic | 9,921,587 | 540,360 | · | 138,848,177 | · | · |
| Weighted average shares, diluted | 9,921,587 | 575,945 | · | 138,848,177 | · | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding